Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway

• Published in: Biochimica et biophysica acta. General subjects Vol. 1862; no. 12; pp. 2688 - 2700
• Main Authors: Sadremomtaz, Afsaneh, Mansouri, Kamran, Alemzadeh, Golnaz, Safa, Majid, Rastaghi, Ahmadreza Esmaeili, Asghari, S. Mohsen
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.12.2018
• Subjects: Angiogenesis; Angiogenesis Inhibitors - pharmacology; Animals; antineoplastic activity; apoptosis; breast neoplasms; cadherins; Cell Line, Tumor; cell proliferation; Cell Proliferation - drug effects; Female; Heterografts; Human Umbilical Vein Endothelial Cells; Humans; MAP Kinase Signaling System - drug effects; metastasis; mice; Mice, Inbred BALB C; neoplasm cells; Neoplasm Metastasis - prevention & control; Neovascularization, Pathologic - prevention & control; neutralization; Peptide design; Peptides - pharmacology; phosphorylation; signal transduction; staining; transcription factor NF-kappa B; Tumor growth; Vascular Endothelial Growth Factor A - physiology; vascular endothelial growth factor receptor-1; Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors; vascular endothelial growth factor receptor-2; Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors; VEGFR1; VEGFR2; weight loss; X-radiation; VEGFR2; Peptide design; Angiogenesis; VEGFR1; Tumor growth

Neutralization of vascular endothelial growth factor receptor 1 (VEGFR1) and/or VEGFR2 is a widely used means of inhibiting tumor angiogenesis. Based on the complex X-ray structures of VEGFA/VEGFR1, VEGFA/VEGFR2, and VEGFB/VEGFR1, a peptide (referred to as VGB) was designed to simultaneously bind to...